Corcept Therapeutics Inc share price logo

Corcept Therapeutics Inc Share Price

NASDAQ: CORT

Mid Cap

$33.84

+0.21

(+0.64%)

as on

Corcept Therapeutics Inc Stock Performance

as on March 25, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $33.00
    $34.11
    downward going graph

    2.48%

    Downside

    0.80%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $28.66
    $117.33
    downward going graph

    15.31%

    Downside

    246.72%

    Upside

    downward going graph

Corcept Therapeutics Inc share price movements today

Previous Close
$33.63
Open
$33.17
Volume
1.1M
Day's Low - High
$33.00 - $34.11
52 Week Low - High
$28.66 - $117.33

Corcept Therapeutics Inc Historical Returns

1 Month Return
-7.15 %
3 Month Return
-59.77 %
1 Year Return
-42.34 %
3 Year Return
+ 54.48 %
5 Year Return
+ 41.6 %

Corcept Therapeutics Inc Stock Fundamentals & Key Indicators

Check Corcept Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$3.7B

EPS (TTM)

0.384

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.22%

PE Ratio (TTM)

42.24

Industry PE ratio

7.867522123893806

PEG Ratio

0.813

EBITDA

45.9M

Revenue (TTM)

761.4M

Profit Margin

13.09%

Return On Equity TTM

15.02%

Corcept Therapeutics Inc Stock Valuation

Track how Corcept Therapeutics Inc P/E has moved over time to understand its valuation trends.

Corcept Therapeutics Inc in the last 5 years

  • Overview

  • Trends

Lowest (22.29x)

March 31, 2024

Industry (7.87x)

March 25, 2026

Today (42.24x)

March 25, 2026

Highest (95.87x)

December 31, 2025

LowHigh

Today’s Price to Earnings Ratio: 42.24x

Corcept Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Corcept Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Corcept Therapeutics Inc image
Corcept Therapeutics Inc
BUY$3.7B41.6%42.2413.09%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$41.4B126.75%133.418.45%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$115.3B112.49%29.6832.94%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$31.6BNA1115.37%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$77.5B58.91%17.6731.41%

Stock Returns calculator for Corcept Therapeutics Inc Stock including INR - Dollar returns

The Corcept Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Corcept Therapeutics Inc investment value today

Current value as on today

₹67,565

Returns

₹32,435

(-32.43%)

Returns from Corcept Therapeutics Inc Stock

₹41,975 (-41.98%)

Dollar Returns*

₹9,541 (+9.54%)

Analyst Recommendation on Corcept Therapeutics Inc Stock

Based on 11 analysts

BUY

90.91%

Buy

9.09%

Hold

0.00%

Sell

Based on 11 analysts, 90.91% of analysts recommend a 'BUY' rating for Corcept Therapeutics Inc. Average target price of $65.4

Corcept Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Corcept Therapeutics Inc.

What analysts predicted

48.26%UPSIDE

Target Price

$65.4

Current Price

$33.84

Analyzed by

11 Analysts

Target

$65.40

Corcept Therapeutics Inc target price $65.4, a slight upside of 48.26% compared to current price of $33.84. According to 11 analysts rating.

Corcept Therapeutics Inc Stock’s Investor Sentiment and Interest

Investment in Corcept Therapeutics Inc Shares on INDmoney has dropped by -64.17% over the past 30 days, indicating reduced transactional activity.

Time period: to

Change:-64.17% versus previous 30 day period

Search interest for Corcept Therapeutics Inc Stock has decreased by -72% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-72% versus previous 30 day period

Corcept Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
123
135
146
163
182
181
157
194
207
202
Gross Profit
121
133
144
161
179
178
154
190
203
199
Operating Income
31
31
29
35
46
25
3
26
10
4
EBITDA
31
32
29
41
47
25
3
27
15
10
Interest Expense
-
3
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
36
36
34
41
52
31
9
31
15
9
Income Tax Expense
5
5
7
6
5
1
-10
-3
4
-14
Net Income
31
31
27
35
46
30
20
35
19
24
Net Profit Margin
25.39%
23.16%
18.91%
21.67%
25.58%
16.71%
12.90%
18.08%
9.32%
12.02%

Corcept Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
81
159
251
306
353
365
401
482
675
761
Gross Profit
79
155
246
300
348
360
396
475
664
748
Operating Income
10
52
89
111
128
124
112
107
136
44
EBITDA
10
52
89
113
130
127
115
108
138
68
Interest Expense
2
0
2
5
5
3
3
-
-
-
Depreciation
-
0
0
2
2
3
2
2
1
1
Income Before Tax
8
52
92
116
131
125
116
124
161
66
Income Tax Expense
-
-76
16
22
25
12
14
18
20
-33
Net Income
8
129
75
94
106
112
101
106
139
99
Net Profit Margin
10.01%
81.11%
30.01%
30.73%
29.96%
30.74%
25.24%
22.00%
20.70%
13.09%

Corcept Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
31
27
35
46
30
20
35
19
98
Operating Cash Flow
5
23
41
73
59
5
43
54
38
Investing Cash Flow
17
-9
-60
-44
-64
-3
70
14
-11
Financing Cash Flow
0
0
-2
-21
-4
-39
-102
-46
-31
Change in Cash
23
14
-21
8
-9
-37
12
22
-4

Corcept Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
129
75
94
106
112
101
106
141
98
Operating Cash Flow
60
115
136
151
167
120
127
198
141
Investing Cash Flow
-73
-90
-117
-119
136
-114
90
-177
69
Financing Cash Flow
-7
-14
-28
12
-302
-17
-148
-28
-220
Change in Cash
-20
10
-10
44
1
-11
69
-7
-7

Global Institutional Holdings in Corcept Therapeutics Inc

Funds
Holdings
Parallel Advisors, LLC
3.64%
TD Global Investment Solutions – TD Epoch
0.77%
NORGES BANK
0.65%
Renaissance Technologies Corp
5.41%
TD Asset Management Inc
0.94%
See all

Corcept Therapeutics Inc News & Key Events

    Insights on Corcept Therapeutics Inc

    Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

    • imgPOSITIVE IMPACT

      Best in 3 Years

      img

      In the last 3 years, CORT has outperformed top 5 stocks with highest market-cap in its industry

    • imgPOSITIVE IMPACT

      Profit Spike

      img

      Netprofit is up for the last 2 quarters, 19.35M → 24.28M (in $), with an average increase of 20.3% per quarter

    • imgNO EFFECT

      Against Peers

      img

      In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 11.4% return, outperforming this stock by 54.9%

    • imgNEGATIVE IMPACT

      Revenue Fall

      img

      Revenue is down for the last 2 quarters, 207.63M → 202.12M (in $), with an average decrease of 2.7% per quarter

    • imgNEGATIVE IMPACT

      Price Dip

      img

      In the last 3 months, CORT stock has moved down by -59.8%

    About Corcept Therapeutics Inc

    leading the field in the discovery of drugs that modulate the effects of cortisol the adverse effects of excess cortisol have been corcept’s focus since the company’s inception. abnormal levels and release of cortisol play a role in a variety of metabolic, oncological, and psychiatric diseases, and we are currently studying a new generation of compounds that may mitigate the effects of excess cortisol. in addition to our work with mifepristone, we have developed over 300 proprietary molecules, advancing the most promising of these to the clinic to see if they can mitigate the effects of excess cortisol and the serious, sometimes life-threatening conditions that may result. all of these compounds competitively block the glucocorticoid receptor (gr), but not the progesterone receptor. scientific literature suggests that competitive gr antagonism may have a role in treating many conditions, including post-traumatic stress disorder, mild cognitive impairment, alzheimer’s disease, alcoholis
    OrganisationCorcept Therapeutics Inc
    Headquarters101 Redwood Shores Parkway, Redwood City, CA, United States, 94065
    IndustryHealth Technology
    CEODr. Joseph K. Belanoff M.D.
    E-voting on sharesClick here to vote

    Key Management of Corcept Therapeutics Inc

    Name

    Title

    Dr. Hazel Hunt Ph.D.

    Chief Scientific Officer

    Ms. Amy Flood

    Chief Human Resources & Communications Officer

    Mr. Roberto W. Vieira

    President of Oncology

    Dr. Joseph K. Belanoff M.D.

    Co-Founder, President, CEO & Director

    Dr. William Guyer Pharm.D.

    Chief Development Officer

    Mr. Joseph Douglas Lyon

    Chief Technology & Accounting Officer

    Ms. Monica Tellado

    President of Emerging Markets

    Mr. Atabak Mokari

    CFO & Treasurer

    Mr. Sean Maduck

    President of Endocrinology

    Mr. Gary Charles Robb J.D.

    Chief Business Officer & Secretary

    FAQs

    What is Corcept Therapeutics Inc share price today?

    Corcept Therapeutics Inc share price today is $33.84 as on at the close of the market. Corcept Therapeutics Inc share today touched a day high of $34.11 and a low of $33.

    What is the 52 week high and 52 week low for Corcept Therapeutics Inc share?

    Corcept Therapeutics Inc share touched a 52 week high of $117.33 on and a 52 week low of $28.66 on . Corcept Therapeutics Inc stock price today i.e. is closed at $33.84,which is 71.16% down from its 52 week high and 18.07% up from its 52 week low.

    What is Corcept Therapeutics Inc's market capitalisation today?

    Corcept Therapeutics Inc market capitalisation is $0.00T as on .

    How to invest in Corcept Therapeutics Inc Stock (CORT) from India?

    1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
    2. Step 2: Search for Corcept Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Corcept Therapeutics Inc Shares that will get you 0.0443 shares as per Corcept Therapeutics Inc share price of $33.84 per share as on March 25, 2026 at 1:29 am IST.

    What is the minimum amount required to buy Corcept Therapeutics Inc Stock (CORT) from India?

    Indian investors can start investing in Corcept Therapeutics Inc (CORT) shares with as little as ₹93.734 or $1 (as of ) using the INDmoney app.
    For example: If you want to invest $10 or ₹937.34 in Corcept Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Corcept Therapeutics Inc share’s latest price of $33.84 as on March 25, 2026 at 1:29 am IST, you will get 0.2955 shares of Corcept Therapeutics Inc. Learn more about fractional shares .

    What are the returns that Corcept Therapeutics Inc has given to Indian investors in the last 5 years?

    Corcept Therapeutics Inc stock has given 41.6% share price returns and 28.4% dollar appreciation to an Indian investor in the last 5 years.
    Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?